| 注册
首页|期刊导航|昆明医科大学学报|培美曲塞联合顺铂与紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床疗效观察

培美曲塞联合顺铂与紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床疗效观察

陈楠 张莹 李恒 郭刚 向旭东 马千里 李高峰

昆明医科大学学报2016,Vol.37Issue(9):96-99,4.
昆明医科大学学报2016,Vol.37Issue(9):96-99,4.

培美曲塞联合顺铂与紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床疗效观察

Observation on the Clinical Efficacy between Pemetrexed Plus Cisplatin and Paclitaxel Plus Cisplatin in the Treatment of Advanced Non-small Eell Lung Cancer

陈楠 1张莹 1李恒 1郭刚 1向旭东 1马千里 1李高峰1

作者信息

  • 1. 昆明医科大学第三附属医院胸外科,云南昆明 650118
  • 折叠

摘要

Abstract

Objective To observe the clinical efficacy and adverse reactions between pemetrexed plus cisplatin and paclitaxel plus cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC).Methods Forty-two cases with non-small cell lung cancer in our hospital from June 2013 to June 2015 were selected.Patients were randomly divided into observation group and control group with 21 cases in each group.The observation group was treated with pemetrexed plus cisplatin and the control group was treated with paclitaxel plus cisplatin.The clinical efficacy and adverse reactions were observed after two courses (21 days of a course) and the statistical analysis was performed.Results In the observation group and control group,response rate and clinical benefit rate were33.33% (7/21),28.57% (6/21) and76.19% (16/21),71.43% (15/21) respectively.No statistical significance were seen between the two groups (P>0.05).The rate of hair loss (23.81%) (5/21) and the total number of adverse reactions (18.37%) (27/147) in the observation group were significantly lower than the rate of hair loss (47.62%) (10/21) and the total number of adverse reactions (25.17%) (37/147) in the control group (P<0.05) No statistical significance was found in the incidence rate of leukopenia,neutropenia,erythropenia,thrombocytopenia,nausea and vomiting and phlebitis between the two groups (P >0.05) Conclusion Pemetrexed plus cisplatin is as effective as paclitaxel plus cisplatin in the treatment of advanced NSCLC with less adverse reactions and is much safer than paclitaxel plus cisplatin.Pemetrexed plus cisplatin is more valuable in the clinical treatment of advanced NSCLC.

关键词

培美曲塞/紫杉醇/顺铂/晚期非小细胞肺癌/临床疗效

Key words

Pemetrexed/Paclitaxel/Cisplatin/Advanced non-small cell lung cancer/Clinical efficacy

分类

医药卫生

引用本文复制引用

陈楠,张莹,李恒,郭刚,向旭东,马千里,李高峰..培美曲塞联合顺铂与紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床疗效观察[J].昆明医科大学学报,2016,37(9):96-99,4.

基金项目

云南省应用基础研究基金资助项目(2010CD185) (2010CD185)

云南省社会发展科技计划基金资助项目(2010CA015) (2010CA015)

昆明医科大学学报

OACSTPCD

1003-4706

访问量0
|
下载量0
段落导航相关论文